TUMOUR
Interval-compressed chemotherapy effective in treatment of localized Ewing sarcoma
This report has been verified
by one or more authors of the
original publication.
J Clin Oncol. 2012 Nov 20;30(33):4148-54. doi: 10.1200/JCO.2011.41.5703. Epub 2012 Oct 22
568 patients with localized Ewing sarcoma were randomized to receive alternating cycles of vincristine - doxorubicin - cyclophosphamide and ifosfamide-etoposide chemotherapy either every 14 or 21 days. Between cycles patients were administered filgrastim and at week 13 all patients received primary tumour treatment. The purpose of this study was to determine whether interval compression was effective in improving the prognosis of patients. At 5.5 years, results indicated that chemotherapy administered every 14 days was more effective than every 21 days, as it significantly increased the event-free survival rate without increasing toxicity.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
